IONIS PHARMACEUTICALS INC — Director's Dealing 2015

Jan 20, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2015-01-15

Reporting Person: Monia Brett P (SVP, Antisense Drug Discovery)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-01-15	Common Stock	M	527	—	Acquired	2462	Direct
2015-01-16	Common Stock	S	201	$67.964	Disposed	2261	Direct
2015-01-15	Common Stock	M	208	—	Acquired	2469	Direct
2015-01-16	Common Stock	S	80	$67.964	Disposed	2389	Direct
2015-01-15	Common Stock	M	1415	—	Acquired	3804	Direct
2015-01-16	Common Stock	S	539	$67.964	Disposed	3265	Direct
2015-01-15	Common Stock	M	1875	—	Acquired	5140	Direct
2015-01-16	Common Stock	S	714	$67.964	Disposed	4426	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-01-15	Restricted Stock Units	$	A	6070	Acquired		Common Stock (6070)	Direct
2015-01-15	Restricted Stock Units	$	M	527	Disposed		Common Stock (527)	Direct
2015-01-15	Restricted Stock Units	$	M	208	Disposed		Common Stock (208)	Direct
2015-01-15	Restricted Stock Units	$	M	1415	Disposed		Common Stock (1415)	Direct
2015-01-15	Restricted Stock Units	$	M	1875	Disposed		Common Stock (1875)	Direct

Footnotes

F1: Acquired pursuant to vesting and release of shares pursuant to a RSU award granted on January 15, 2012.

F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2012.

F3: Acquired pursuant to vesting and release of shares pursuant to a RSU award granted on January 30, 2013.

F4: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013.

F5: Acquired pursuant to vesting and release of shares pursuant to a RSU award granted on January 15, 2014.

F6: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014.

F7: Each Restricted Stock Unit represents a contingent right to receive one share of Isis common stock, or its equivalent cash value.

F8: Grant 1/15/2015 to reporting person of Restricted Stock Units under the Isis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2016. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2019. The RSU is vested as to 0 shares on January 15, 2015.

F9: Restricted Stock Unit Award granted on January 15, 2012. Restricted Stock Units vest in equal annual installments, the first installment vested on January 15, 2013. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2016.

F10: Restricted Stock Unit Award granted on January 30, 2013. Restricted Stock Units vest in equal annual installments, the first installment vested on January 15, 2014. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2017.

F11: Restricted Stock Unit Award granted on January 15, 2014. Restricted Stock Units vest in equal annual installments, the first installment vested on January 15, 2015. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2018.